Which big biopharma player should gamble $34B on a ripe rare-disease M&A target? An action-hungry top analyst fills in the blanks
Geoffrey Porges has been openly unhappy with Ludwig Hantson and the team that runs Alexion $ALXN. Their discount M&A deals don’t make much sense, as underscored by a suffering share price, and he believes the company would have been better offering dividends to investors than squandering it on a misguided BD strategy.
In the best of all worlds, Alexion’s investors might be best served with a premium takeout, and Porges has been thinking about which potential buyer makes the most sense.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.